A closer look at industry issues

 

As we announced several weeks ago, FiercePharma will be featuring a new special section called Industry Voices. A variety of columnists will discuss issues affecting the pharmaceutical industry and examine the trends that are changing the way drug makers do business. We hope this feature will give you deeper insight into larger issues that don't always make the daily news cycle.

Our first columnist is Mark Senak, an industry expert with over twenty years of experience in law, communications, public health and public relations. He is also the author of Eye on FDA, a popular blog covering the ins and outs of FDA news and policy. Scroll down to check out his article on the recent upheaval at the FDA, or click here to read it online. - Maureen

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.